Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 20.4% in April

Key Points

• Short interest down 20.4% in April to 12,887 shares, leaving a short-interest ratio of about 3.5 days based on average daily volume.
• Analyst coverage is mixed (two Buys, one Hold, one Sell) with a consensus rating of "Hold" and a consensus price target of $8.38, while the stock trades near $4.23 and the company recently reported a quarterly EPS miss (‑$0.41).
• Institutional activity includes SmartHarvest's new 12,311‑share position (~$54K) and overall institutional ownership of about 26.55%, with a market cap around $170.8 million.

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report) saw a large decrease in short interest in April. As of April 15th, there was short interest totaling 12,887 shares, a decrease of 20.4% from the March 31st total of 16,194 shares. Based on an average daily volume of 3,644 shares, the short-interest ratio is currently 3.5 days. Approximately 0.0% of the company's shares are short sold.

Wall Street Analysts Forecast Growth

MOLN has been the subject of a number of research reports. TD Cowen reaffirmed a "buy" rating on shares of Molecular Partners in a research note on Monday, March 16th. HC Wainwright reaffirmed a "buy" rating and issued a $13.00 price objective on shares of Molecular Partners in a research note on Wednesday, April 22nd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Molecular Partners in a research note on Friday, April 10th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $8.38.

Molecular Partners Trading Down 4.9%

Shares of MOLN stock traded down $0.22 during mid-day trading on Thursday, reaching $4.23. The stock had a trading volume of 1,518 shares, compared to its average volume of 2,667. The stock's 50-day moving average price is $4.47 and its two-hundred day moving average price is $4.30. Molecular Partners has a 52-week low of $3.41 and a 52-week high of $5.36. The firm has a market capitalization of $170.81 million, a PE ratio of -2.13 and a beta of 1.11.

Molecular Partners (NASDAQ:MOLN - Get Free Report) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.03). On average, equities research analysts forecast that Molecular Partners will post -1.4 earnings per share for the current year.

Institutional Investors Weigh In On Molecular Partners

An institutional investor recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC bought a new position in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 12,311 shares of the company's stock, valued at approximately $54,000. Hedge funds and other institutional investors own 26.55% of the company's stock.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company's technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company's development pipeline spans infectious diseases, ophthalmology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.